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Abstract
Background: A major barrier to accessing free government-provided antiretroviral treatment
(ART) in South Africa is the shortage of suitably skilled health professionals. Current South African
guidelines recommend that only doctors should prescribe ART, even though most primary care is
provided by nurses. We have developed an effective method of educational outreach to primary
care nurses in South Africa. Evidence is needed as to whether primary care nurses, with suitable
training and managerial support, can initiate and continue to prescribe and monitor ART in the
majority of ART-eligible adults.
Methods/design: This is a protocol for a pragmatic cluster randomised trial to evaluate the
effectiveness of a complex intervention based on and supporting nurse-led antiretroviral treatment
(ART) for South African patients with HIV/AIDS, compared to current practice in which doctors
are responsible for initiating ART and continuing prescribing. We will randomly allocate 31 primary
care clinics in the Free State province to nurse-led or doctor-led ART. Two groups of patients aged
16 years and over will be included: a) 7400 registering with the programme with CD4 counts of ?
350 cells/mL (mainly to evaluate treatment initiation) and b) 4900 already receiving ART (to
evaluate ongoing treatment and monitoring). The primary outcomes will be time to death (in the
first group) and viral suppression (in the second group). Patients' survival, viral load and health
status indicators will be measured at least 6-monthly for at least one year and up to 2 years, using
an existing province-wide clinical database linked to the national death register.
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Background
South African government health services started in 2004
to provide free ART to HIV-infected patients with CD4
counts ? 200 cells/µl or stage 4 AIDS, but by 2007 only a
third of patients who need ART were receiving it [1]. Cov-
erage is even lower in many other African and Asian coun-
tries [1]. The major bottleneck is due to reliance on
doctors to prescribe ART, including starting treatment.
Doctors are generally only available in hospitals and large
urban health centres, whereas most public sector primary
care clinics are staffed by nurses. Therefore better use of
nurses is a compelling way to expand access and avoid
delays in starting treatment. We urgently need to know
whether most patients with HIV/AIDS can start and con-
tinue ART without doctors' involvement. If so, they could
start treatment earlier, and thus avoid disease progression
and death.
At present in South Africa only doctors may prescribe ART,
in keeping with national guidelines. In the Free State prov-
ince, where this trial is located, doctors initiate ART and
repeat prescriptions when reviewing patients 6-monthly,
with monthly visits to nurses in between. It is still widely
assumed that ART is too difficult and risky to be entrusted
to nurses because of drug side effects and resistance. But
many eligible patients continue to die because of delays in
starting ART. Our evaluation of the Free State province's
ART programme to December 2005 found that, of 4570
patients followed for one year or until death, 53% died,
87% of them before they started ART [2]. However when
ART was received it reduced mortality by 87%, during up
to 19 months of follow up. Most patients with advanced
HIV/AIDS have no contra-indications to ART, and can be
managed by first line ART regimes (stavudine, lamivudine
and efavirenz, or stavudine, lamivudine and nevirapine).
It is thus likely that, with appropriate training and sup-
port, nurses can manage most patients effectively, leaving
doctors to manage the minority at high risk or with com-
plications.
We believe there is equipoise about whether a nurse-led
system, based in primary care and with educational and
managerial support, can be as effective as the current doc-
tor-led system. On the one hand, nurses have less medical
expertise than doctors and so may provide inferior care.
On the other hand, if they can start treatment earlier they
will probably obtain better outcomes.
A Cochrane review identified 16 randomised trials com-
paring primary care provided by doctors and nurses in
other contexts and found that nurses could manage gen-
eral medical conditions, including chronic diseases and
cardiovascular risk factors, as effectively as doctors can [3].
However nurses were generally not more cost effective,
because of lengthier consultations, more tests, and costs
of medical supervision. None of these trials evaluated
AIDS care, which is potentially more complex and risky
than the types of care investigated by these trials. A
Cochrane review on organisation and delivery of HIV/
AIDS care highlighted the absence of trial evidence from
developing countries [4]. Our own literature review found
no randomised trials comparing ART care provided by
doctors with ART care provided by nurses or other health
workers. Recent studies from Africa [5,6] and other devel-
oped countries [7-9] described new roles for nurses in
AIDS care, but they were not randomised trials and none
compared doctors or nurses with other health workers.
The trial builds on two randomised trials we carried out in
the same setting between 2003 and 2007. The first, Practi-
cal Approach to Lung Health in South Africa ("PALSA")
trial, was a cluster randomised trial in the 40 largest pri-
mary care clinics in the Free State [10]. It evaluated a mul-
tifaceted method of educational outreach to clinic nurses
based on syndromic algorithmic guidelines for integrated
management of adult lung disease, building on a WHO
initiative. It showed that the intervention was effective
and cost effective in improving tuberculosis case detection
and asthma treatment. The second, "PALSA PLUS", cluster
randomised trial evaluated the extension of the guideline
and training to cover HIV/AIDS care in the 15 clinics then
providing ART. It demonstrated effectiveness in increasing
cotrimoxazole prophylaxis and tuberculosis case detec-
tion among HIV/AIDS patients (paper submitted), which
led to its adoption as a provincial programme. However at
that time only doctors could initiate ART. We simultane-
ously conducted a cohort study of all 14267 patients
enrolled on the HIV/AIDS programme to the end of 2005,
discussed above [11]. These studies have demonstrated
the effectiveness of our educational method and guide-
lines for improving quality of primary nursing care pro-
vided by nurses, the research value of these programme
data, and the impact of our research on policy.
In another randomised trial in South Africa, which by
April 2008 had ended recruitment but not yet reported
results, patients receiving ART in two clinics were ran-
domised to be monitored either by a HIV-trained doctor
or either of two HIV-trained primary care nurses (Clinical-
Trials.gov NCT00255840). Key differences between our
current trial and that one are: a) our trial evaluates a com-
plex intervention including training, staffing, and man-
agement support as well as professional substitution, and
b) our trial includes all clinics and patients involved in an
entire province's HIV/AIDS programme. Our search of
randomised trial registers (Controlled Clinical Trials
meta-register and linked registers) identified no other
planned, ongoing or completed randomised trials com-
paring ART provision by doctors with ART provision by
nurses or other health professionals.Trials 2008, 9:21 http://www.trialsjournal.com/content/9/1/21
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The Free State health department has therefore decided to
support this trial and to decide whether to implement
nurse-led ART based on the trials' results. Despite national
guidelines, its Provincial Pharmaceutical and Therapeu-
tics Committee is legally authorised to permit nurses to
prescribe Schedule 4 drugs such as antiretrovirals, and has
done so for intervention clinics in this trial. The National
Department of Health and the main patient advocacy
group in South Africa, the Treatment Action Campaign,
also support the trial and are keenly interested in the
results. The timing of this trial is thus critical for policy
making.
Methods/Design
Design
Pragmatic cluster randomised trial with clinics ran-
domised to two parallel arms
Aims
To compare the effectiveness of a primary care system
based on nurse-led ART, with the current system based on
doctor-led ART.
Inclusion criteria
Clinics
All 31 nurse-staffed primary care clinics providing ART as
part of the public-sector treatment program, in the Free
State province, South Africa.
Patients
The study population will be two subgroups of HIV-
infected patients aged ? 16 years and over enrolled with
the Free State Comprehensive Care, Management and
Treatment of HIV and AIDS Program. Children aged <16
are excluded because management by doctors is still con-
sidered necessary, because of complexities of drug dosages
and detecting complications.
Subgroup 1
Patients with CD4 count ? 350 cells/µl and not yet receiv-
ing ART. These patients are either eligible for ART (CD4 ?
200) or likely to become eligible during the trial period
(CD4 >200 – 350). The latter patients, with CD4s
between 200 and 350 cells/µl, are included to assess the
ability of nurses in intervention clinics to monitor
patients up to the time they become eligible for ART and
then to initiate ART promptly.
Subgroup 2
Patients who have already received ART for at least 6
months. This subgroup is included so as to enable evalu-
ation of the effect of the intervention on longer term ART
monitoring and re-prescriptions, while restricting the
trial's follow-up period.
Interventions
Control clinics
Current practice will be followed: 1. Patients eligible for
ART (with CD4 ? 200 or stage 4 AIDS) will be referred to
a doctor who will initiate and repeat prescriptions for ART
and review patients every six months. Between visits to
doctors, patients will be seen monthly by nurses (who
may not prescribe ART) and will collect their medication.
2. Nurses will continue to use PALSA PLUS algorithmic
guidelines for management of HIV/AIDS, sexually trans-
mitted infections, and tuberculosis, having been trained
to do so. These guidelines state that nurses do not pre-
scribe ART. 3. Clinics will continue to receive routine
managerial support and monitoring.
Intervention clinics
STRETCH is a complex intervention, to be implemented
in intervention clinics, that will differ from control clinics
as follows.
1. Designated nurses in each clinic will be authorised to
prescribe ART. In addition to the training provided to con-
trol clinic nurses, they will receive training at their clinics
covering ART prescribing, drug effects and side-effects,
and use of algorithmic clinical practice guidelines includ-
ing criteria for identifying patients requiring referral to a
doctor. Nurses will not initiate ART in patients meeting
the following criteria criteria but will refer them to the
doctor (CD4 < 50, Stage 4 AIDS, previous ART, bed- or
wheelchair-bound, using drugs other than cotrimoxazole
or vitamins, pregnant, weight < 40 kg or body mass index
>28). Doctors will also receive training about the guide-
lines so that they can support the nurses. These "ART
nurses" will prioritise assessment and ART initiation for
ART-eligible patients and carry out most treatment moni-
toring. Non-ART-prescribing nurses working in the ART
clinics and surrounding clinics, who have received the
same training as control clinic nurses, will provide routine
HIV care to patients not yet eligible for ART, and refer
them to ART-prescribing nurses as soon as they meet cri-
teria for treatment. To relieve the workload of ART pre-
scribing nurses, supportive components of ART care
(apart from ART prescribing) such as drug readiness train-
ing and serial CD4 monitoring prior to ART initiation,
will be decentralised to other primary care clinics that
have staff trained in these components of ART care. This is
intended to relieve the workload on ART prescribing
nurses.
2. Managerial decisions relating to ART will be delegated
to clinic managers. Clinics will receive additional manage-
rial support through regular clinic visits by designated
STRETCH co-ordinators. These arrangements, which
include managerial steps to be taken, definitions of new
staff roles, tips on dealing with likely problems, contactTrials 2008, 9:21 http://www.trialsjournal.com/content/9/1/21
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details of programme managers, and authorisation of
nurse prescribing, are clearly described in the STRETCH
Implementation Toolkit – a 30 page document provided
to each clinic and trained nurse.
Randomisation
Clinics were randomised to either of two arms. Randomi-
sation was stratified by referral hospital-based "treatment
site", because differences between these sites may con-
found clinic level ART care. However stratification was not
used in one district where assessment and treatment are
combined. Randomisation was carried out by the trial
statistician (Lombard) before the intervention and patient
recruitment started. N-Query Advisor was used to generate
the allocation codes.
Allocation concealment
Blinding and masking of patients and clinicians are not
possible because, in each clinic, all eligible patients will be
managed in the same way. However the trial statistician
who carried out randomisation did not know the charac-
teristics of the clinics being randomised, and the primary
statistical analysis will be blinded to allocation.
Endpoints
Primary outcomes
Subgroup 1
Time from enrolment to death. Survival analysis will be
censored 12 months after the last patient has been
recruited. Mortality is the most important health outcome
and it is common – currently 28% of enrolled ART-eligi-
ble patients die within a year or enrolment. Deaths will be
identified from programme data and by linkage with the
national mortality register [2,11]. Because it is routinely
recorded independently of the programme, with most
deaths occurring in hospital or at home, measurement is
less dependent on clinic professionals' practice, unlike
adverse clinical outcomes or side effects of treatment,
which require clinical skills to detect. This outcome
reflects both the effectiveness of the health system in ini-
tiating treatment, and the effectiveness of ART once
started.
Subgroup 2
Undetectable viral load (<400 copies/mL) one year after
recruitment. This demonstrates continuing ART effective-
ness, including adherence and treatment monitoring.
Excess detectable viral loads will show whether the addi-
tional burden on nurses of initiating ART undermines the
effectiveness of treatment monitoring, including dealing
with poor adherence or resistance. Mortality would be a
less appropriate primary outcome in this subgroup
because mortality on ART is lower (17% per year [2]) and
because it would probably take more than a year for sub-
optimal monitoring to lead to death.
Secondary outcomes
Subgroup 1
Process measures
time from enrolment to starting ART; proportion of
patients who started ART during the study period; propor-
tion with sputa submitted for TB screening; proportion
diagnosed with tuberculosis; proportion receiving cotri-
moxazole prophylaxis; nurse and doctor visits to ART pro-
gramme.
Health measures
proportion with viral loads <400 copies/mL; baseline
CD4 count of patients starting ART; changes in CD4 and
weight; hospital admissions.
Subgroup 2
Process measures
proportion lost to follow-up; proportion with sputa sub-
mitted for TB screening; proportion diagnosed with tuber-
culosis; proportion receiving cotrimoxazole prophylaxis;
nurse and doctor visits to ART programme.
Health measures
time from recruitment to death; changes in CD4 and
weight; hospital admissions.
Side effects: reporting and quantification
Adverse AIDS outcomes and adverse ART reactions are
expected among some patients and will be monitored:
￿ Patients with evidence of adverse ART effects (severe
rashes, lactic acidosis, severe anaemia) will be identified
by the nurses and doctors monitoring them, who will
record these events.
￿ Deaths known to ART providers will be recorded. Mor-
tality will also be tracked by monthly linkage with deaths
notified on the national population register.
￿ Hospital admissions, and reasons for admissions, will
be continuously monitored by linkage with health depart-
ment admissions data.
Statistical analysis plan
Sample size
For subgroup 1, patients newly enrolled on the pro-
gramme, sample size is calculated for a superiority trial (2
sided), because we hope to show decreased mortality in
the nurse-led arm owing to reduced delay to starting ART.
We expect to recruit at least 7400 newly enrolled patients
during the first 12 months of the trial, since 4000 eligible
patients were enrolled in trial clinics between 1 September
and mid-December 2007. Previous programme data show
that 29% of patients followed for at least a year died
within one year, with an intra-clinic correlation coeffi-Trials 2008, 9:21 http://www.trialsjournal.com/content/9/1/21
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cient (ICC) of 0.01. A sample size of 6000 (3000 per arm)
would provide 90% power to detect a 6% difference in
one-year mortality (24% vs 30%) at the 5% significance
level, assuming ICC = 0.01. To cater for a 10% dropout the
sample size has to be increased to 7400 in total (6000/((1-
0.1)^2). Furthermore, Cox regression of time to death will
have more power than comparison of proportions dying
within a year.
For subgroup 2, patients already receiving ART, sample
size is calculated for an equivalence trial, because we hope
to show that nurse-led ART will be just as effective in sup-
pressing HIV. We expect to recruit at least 4000 such
patients since 2000 eligible patients were identified in
trial clinics between 1 September and mid-December
2007. Previous programme data show that 82% of
patients who had received ART for 12 months had unde-
tectable viral loads, with an intra-clinic correlation coeffi-
cient of 0.005. A sample size of 4000 (2000 in each arm)
would provide 90% power to reject the null hypothesis of
non-equivalence in favor of the alternative hypothesis
that the proportions patients with undetectable viral load
in the two groups are equivalent using a 6% equivalence
limit (i.e. within 6% of 80% in either arm), at the 5% sig-
nificance level, assuming ICC = 0.005. To cater for a 10%
dropout the sample size has to be increased to 4900 in
total (4000/((1-0.1)^2).
Types of analyses
Statistical analyses will be by intention to treat. For analy-
sis of mortality, patients with only one clinic contact will
be excluded; if the proportions of patients with only one
contact differ between trial arms, these analyses will be
adjusted for the clinic-level proportions with only one
contact. The statistical methods will be:
￿ Time to death: Cox proportional hazards regression
￿ Proportion with undetectable viral load, proportion
alive after one year and other binary outcomes: Logistic
regression
￿ CD4 and body weight: Linear regression, adjusting for
baseline values
￿ Time to new diagnosis of tuberculosis: Cox proportional
hazards regression
￿ Health care utilisation rates, and sputa submitted to
detect tuberculosis: Poisson regression
Analyses will be at patient level and account for the strat-
ified randomisation and intra-clinic clustering of out-
comes. In secondary analyses we will also adjust for
baseline confounders, if present.
Subgroup analyses
Patients with different CD4 levels at entry into trial (eg
>200, ? 200 and >100, ? 100 cells/µl) and, among sub-
group 1 patients: patients on ART at end of follow-up,
patients eligible for ART but not receiving it at end of fol-
low-up, and patients not yet eligible for ART at end of fol-
low-up.
Interim analyses, stopping rules and independent data 
monitoring committee
An independent data safety and monitoring committee,
including a statistician, has been established. An interim
analysis of the primary outcomes is planned one year after
recruitment starts. The trial statistician (Lombard) will
carry out the analysis, blinded to allocation, and report
the results to the data safety and monitoring committee. If
there is a highly significant (p < 0.001) difference in any
primary outcome a panel comprising the researchers and
Free State Department of Health managers will meet to
discuss whether to terminate the trial.
Ethical issues
The protocol was approved by the Research Ethics Com-
mittees of the University of Cape Town and University of
Free State Medical Schools.
Patients with HIV/AIDS are at risk of adverse outcomes.
However the treatment programme aims to improve out-
comes, and there is equipoise as to whether patients in
either arm would be at greater risk. According to provin-
cial health department policy the intervention would
probably be implemented incrementally in any case. The
effects of the proposed research will be to randomly allo-
cated implementation, and to provide training, manage-
rial support and evaluation to ensure optimal
implementation.
Professionals and managers in each clinic have consented
to their clinic taking part in the trial. However it is not fea-
sible to obtain patients' consent to be randomised to
intervention or control arms, because randomisation will
be at clinic level. Intervention- and control-type care can-
not be provided within the same clinic because of the
practicalities of clinic staffing, training and management,
and because within-clinic randomisation would severely
contaminate the trial. Even if patients preferred doctor- or
nurse-led care or did not consent to take part in the trial,
they would still necessarily receive the type of care that the
clinic was allocated to provide [12].
Patients will not be asked for their consent for their med-
ical records to be used for this research because it is not
feasible. That is, programme managers and health profes-
sionals have insisted that obtaining such consent from all
eligible patients would be a serious obstacle to wideningPublish with BioMed Central    and   every 
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access to HIV/AIDS care. This is because of a) the many
procedures already involved in patient enrolment, b) cur-
rent delays in providing effective treatment and c) the
large scale of the programme, with over a thousand new
enrolments per month.
However we will adhere to the ethical principles for use of
medical records without patients' consent [13], as follows.
The research has a clear public benefit. We have obtained
approval for the study from the Research Ethics Commit-
tees of the Faculties of Health at the Universities of Cape
Town and Free State, and from the lead doctors and nurses
managing the programme. Use of the data for research
will not influence decisions about individuals' care. The
data are already being used by members of the research
team for programme evaluation on behalf of the provin-
cial health department, and for observational evaluation
of ART effectiveness in the programme cohort. Only a
small number of data managers have access to personal
identifiers. Anonymised unlinked data (without names or
national ID numbers) will be provided only to selected
members of the research team – the principal investiga-
tors, the lead statistician, the data monitoring and ethics
committee statistician and the health economist. There
are hundreds of patients in each clinic so individuals can-
not be identified from clinic names. Data with patient
identifiers will be securely stored at the Lung Institute,
University of Cape Town, and anonymised unlinked data
will be securely stored at the University of East Anglia and
the South African MRC.
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